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Genome-wide association studies (GWAS) have identified numerous loci associated with various complex
traits for which the underlying susceptibility gene(s) remain unknown. In a GWAS for high-density lipopro-
tein-cholesterol (HDL-C) level, one strongly associated locus contains at least two biologically compelling
candidates, methylmalonic aciduria cblB type (MMAB) and mevalonate kinase (MVK). To detect evidence
of cis-acting regulation at this locus, we measured relative allelic expression of transcribed SNPs in five
genes using human hepatocyte samples heterozygous for the transcribed SNP. If an HDL-C-associated
SNP allele differentially regulates mRNA level in cis, samples heterozygous both for a transcribed SNP
and an HDL-C-associated SNP should display allelic expression imbalance (AEI) of the transcribed SNP.
We designed statistical tests to detect AEI in a comprehensive set of linkage disequilibrium (LD) scenarios
between the transcribed SNP and an HDL-C-associated SNP (rs7298565) in phase unknown samples. We
observed significant AEI of 22% in MMAB (P 5 1.4 3 10213, transcribed SNP rs11067231), and the allele
associated with lower HDL-C level was associated with greater MMAB transcript level. The same rs7298565
allele was also associated with higher MMAB mRNA level (P 5 0.0081) and higher MMAB protein level (P 5
0.0020). In contrast, MVK, UBE3B, KCTD10 and ACACB did not show significant AEI (P  0.05). These data
suggest MMAB is the most likely gene influencing HDL-C levels at this locus and demonstrate that measuring
AEI at loci containing more than one candidate gene can prioritize genes for functional studies.
INTRODUCTION
Recent genome-wide association studies (GWAS) have ident-
ified novel variants at 14 loci associated with high-density
lipoprotein-cholesterol (HDL-C) levels (1–3). One
HDL-C-associated locus on chromosome 12 is strongly signifi-
cant (P ¼ 1.2  10210, rs2338104, n ¼ 19 793), independently
replicates across multiple studies, and is associated with a
0.48 mg/dl per allele change in HDL-C levels (2,3). This locus
contains many strongly associated common SNPs [minor allele
frequency (MAF) . 0.05] that exhibit high pairwise linkage dis-
equilibrium (LD) with each other, span a 175 kb region and
encompass four genes. At least two genes demonstrate biological
functions relevant to cholesterol biology. MethylMalonic acid-
uria cblB type (MMAB) encodes the mitochondrial enzyme
cob(I)alamin adenosyltransferase that catalyzes the formation
of adenosylcobalamin, a critical cofactor in the catabolism of
amino acids, lipids and cholesterol (4). Mevalonate kinase
(MVK) encodes the essential early enzyme MVK necessary for
the synthesis of isoprenoids, key intermediates in cholesterol bio-
synthesis (5). Two other genes at the locus not obviously relevant
to cholesterol biology are KCDT10, a member of the polymerase
delta-interacting protein 1 gene family (6), and UBE3B, a novel
member of the ubiquitin 3 ligase family (7). A further plausible
candidate located .150 kb from these genes is ACACB, which
regulates fatty acid oxidation and modulates lipid metabolism
(8). Given the presence of more than one biological candidate,
a primary aim of this study was to identity the gene most likely
to influence HDL-C level.
Genetic variation at the transcript level contributes to the
phenotypic variation between individuals (9). Cis-acting var-
iants are estimated to be responsible for at least 25–35% of
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inter-individual differences in gene expression (10) and func-
tional cis-acting variants can affect transcription, mRNA-
processing, splicing, stability and translation (10).
To identify evidence of cis-acting regulation associated with
HDL-C level, we quantified relative allelic expression in
human hepatocytes heterozygous for transcribed SNPs in
MMAB, MVK, UBE3B, KCTD10 and ACACB. Hepatocytes
were chosen for this study because they are a major site of
HDL biosynthesis and lipidation (11), and HDL-C is trans-
ported to the liver and taken up by hepatocytes following
release from peripheral cells (12). For allelic expression
imbalance (AEI) analysis, measurement of allele-specific
mRNA levels is made within individual samples. Therefore,
in the absence of interactions, relative transcript levels are
unaffected by sources of variation such as environmental
and trans-acting genetic factors. Here, we use real-time PCR
to detect AEI at a locus on chromosome 12 associated with
HDL-C level. We designed simple-to-implement statistical
tests for AEI that are tailored to the observed LD between
trait-associated SNPs and transcribed tested SNPs. Our
results provide evidence suggesting that MMAB is a likely sus-
ceptibility gene at this locus.
RESULTS
AEI at a chromosome 12 locus associated with HDL-C
level
To test whether a cis-acting HDL-C-associated SNP affects
transcript levels, we measured relative allelic cDNA levels
of MMAB, MVK, UBE3B, KCTD10 and ACACB in human
hepatocytes using quantitative real-time PCR and one to two
SNPs per gene. Results for MMAB were followed up by
testing for AEI using two additional SNPs. AEI can only be
detected in samples heterozygous for a transcribed SNP,
hence for each of 10 transcribed SNPs, 35–90 hepatocyte
samples were first screened for genotype heterozygosity, and
AEI was subsequently evaluated in 14–45 samples heterozy-
gous for the transcribed SNP (Table 1). The pattern of AEI
caused by an HDL-C-associated SNP will differ depending
on the LD between the transcribed SNP and the
HDL-C-associated SNP. We considered a comprehensive set
of LD scenarios and used different statistical tests to assess
AEI for different scenarios (Materials and Methods and
Fig. 1).
For each of 10 transcribed SNPs, Figure 2 shows the percen-
tage of one allele present in genomic DNA (gDNA) and in
cDNA stratified by genotype of representative
HDL-C-associated SNP rs7298565 (G allele associated with
lower HDL-C level). For an MMAB SNP in strong LD (r2 ¼
0.94, D0 ¼ 1.0) with rs7298565, we observed significant AEI
(rs877710; PgDNA ¼ 2.4  10
29, ncDNA het ¼ 20, Fig. 2A).
The C allele of rs877710 showed 22% higher expression
than the G allele. A second MMAB SNP tested in additional
samples also showed strongly significant AEI (rs11067231;
PgDNA ¼ 1.4  10
213, ncDNA het ¼ 45, Fig. 2B); the C allele
of rs11067231 demonstrated a similar 22% higher expression
than the G allele. The C alleles of both rs877710 and
rs11067231 are on the same haplotype as the G allele of
rs7298565 in 44 of 45 samples, thus the G allele of
rs7298565 is associated with higher MMAB expression.
AEI in MMAB was also tested using two SNPs in lower LD
with rs7298565 and consequently with lower power to detect
AEI (Table 1): rs2241201 (r2 ¼ 0.43, D0 ¼ 1.0; Fig. 2C) and
rs11067233 (r2 ¼ 0.11, D0 ¼ 0.70; Fig. 2D). We observed
AEI in the same direction as for rs877710 and rs11067231.
The G allele of rs2241201 demonstrated 20% higher
expression than the C allele (PgDNA ¼ 7.1  10
24), and pres-
ence of AEI was confirmed using the cDNA t-test (PcDNA ¼
6.5  1023), which compares the cDNA samples homozygous
for the rSNP to the cDNA samples heterozygous for the rSNP
and reduces the risk of bias for any technical difference
present when comparing gDNA to cDNA. At rs11067233
the C allele demonstrated 15% higher expression than the G
allele (PgDNA ¼ 8.6  10
24), although the evidence of AEI
using the cDNA t-test (PcDNA ¼ 0.046) would not withstand
correction for multiple SNPs tested (Materials and Methods).
In MVK, only one transcribed SNP with MAF . 0.01 was
available for study, rs7957619. No evidence of significant
AEI was observed (PgDNA ¼ 0.10; PcDNA ¼ 0.21; Fig. 2E).
Additionally, no AEI or only marginally significant AEI was
observed for five SNPs in KCTD10 (Fig. 2F), UBE3B
(Fig. 2G and H) and ACACB (Fig. 2I and J). Taken together,
these results argue that a cis-acting SNP is acting on MMAB
leading to altered quantities of mRNA.
Power to detect AEI
We estimated the power to detect AEI in each transcribed SNP
based on the 22% allelic expression difference between
transcribed SNP alleles B and b observed for MMAB SNP
rs11067231 (Table 1 and Supplementary Material, Tables
S1, S2 and S3). For MVK, the power to detect AEI was
100%, and for KCTD10, UBE3B and ACACB power ranged
from 93 to 100% for the most powerful test (Table 1). Thus,
we had good power to detect AEI if it existed in these other
genes with the strength observed in MMAB.
For each transcribed SNP, we also estimated the AEI that
could be detected with 80% power in the samples tested
(Table 1). For the four SNPs in MMAB, we estimate that we
had 80% power to detect AEI of 6.1–34.2%. For the remain-
ing genes the most powerful test had 80% power to detect AEI
of 5.0–16.8%. In addition, AEI and power to detect AEI was
estimated at significance level 0.05 (Supplementary Material,
Table S1) and exclusively in samples of Caucasian ancestry
(Supplementary Material, Tables S2 and S3). Similar results
indicate that population stratification was not a factor affecting
this study (Supplementary Material, Tables S2 and S3).
Higher hepatocyte MMAB mRNA level is associated with
the rs7298565 allele associated with lower HDL-C level
To determine whether total level of mRNA was associated
with genotypes of the HDL-C-associated SNP rs7298565,
mRNA level was measured in all available hepatocyte
samples (n ¼ 89). We observed a significant association
between RNA batch and mRNA level for each gene (P ,
0.001), and consequently included RNA batch as a covariate
in the analysis. Using linear regression under an additive
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genetic model, we found a significant association between
higher levels of MMAB mRNA and the rs7298565 G allele
(P ¼ 0.0081; Fig. 3A). No significant association was
observed between rs7298565 and total mRNA level of MVK,
KCTD10, UBE3B or ACACB (Fig. 3B–E).
Higher hepatocyte MMAB protein level is associated with
the rs7298565 allele associated with lower HDL-C level
To determine whether protein level of MMAB was also
associated with rs7298565 genotype, we measured protein
level in 33 hepatocyte samples (Fig. 4A). Using linear
regression under an additive genetic model, we found a signifi-
cant association between higher levels of MMAB protein and
the rs7298565 G allele (P ¼ 0.0020; Fig. 4B). This result is
consistent with existence of a functional SNP that has a
cis-acting regulatory effect to increase level of MMAB and
decrease HDL-C level.
DISCUSSION
Cis-acting regulatory variants affecting gene expression are
predicted to regulate expression of a large proportion of
human genes (9,13,14) and are likely to account for many of
the SNP-trait associations at susceptibility loci identified
through GWAS. Our recent GWAS identified a region on
chromosome 12 containing SNPs strongly associated with
plasma HDL-C level (3). In the current study, we selected
the strongly HDL-C-associated SNP rs7298565 to represent
these SNPs and asked whether rs7298565 was associated
with cis-acting regulatory activity in five positional candidate
genes. We demonstrated that the G-allele associated with
lower HDL-C level is associated both with higher levels of
MMAB transcript based on AEI and gene expression and
with higher MMAB protein levels.
AEI has been used to identify genes influenced by cis-acting
regulatory SNPs (rSNPs; 15–18), and our results suggest that
measuring AEI has good potential to help prioritize functional
gene candidates in association regions containing more than
one candidate gene. However, successful AEI experiments
require that each candidate gene contain at least one
common transcribed SNP such that sufficient informative het-
erozygous samples are available. In addition, the genes in
which AEI is to be tested must be expressed in an available
tissue relevant to the associated trait. In this study, we inves-
tigated common transcribed SNPs (MAF . 0.01) in each
gene of interest in human hepatocytes.
We describe a statistical strategy that allowed us to evaluate
AEI for transcribed SNPs that exhibit any observed level of
LD with an HDL-C-associated SNP (Fig. 1 and Table 1) in the
absence of information regarding haplotype phase. This strategy
allowed us to evaluate all genes of interest. In each test, we com-
pared the AEI in cDNA from samples heterozygous for the
HDL-C-associated SNP to a reference, either gDNA from the
entire set of heterozygous samples or cDNA from samples
homozygous for the HDL-C-associated SNP. Pairs of SNPs
with r2 ¼ 1.0, D0 ¼ 1.0 have the highest power to detect associ-
ation because the gDNA reference group has the largest sample
size. However, this comparison may also be subject to bias if, in
the absence of AEI, there is a technical difference in the percent
allele detected in gDNA compared with cDNA. For example,
MMAB transcribed SNP rs11067233 shows 47% C allele in
the gDNA but 51% C allele in the cDNA of HDL-C SNP
homozygotes, and this difference could cause an over (or
under) estimation of AEI. For SNPs in which r2 , 1 between
the transcribed SNP and the HDL-C associated SNP, using the
cDNA reference group reduces power but also the risk of bias
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MMAB rs877710 20 0.94/1.0 t-test gDNA 1.0 9.6 22 2.4  1029
MMAB rs11067231 45 0.94/1.0 t-test gDNA 1.0 6.1 22 1.4  10213
MMAB rs11067233 27 0.11/0.70 t-test gDNA 0.62 25.6 15 8.6  1024
t-test cDNA 0.54 28.0 0.046
F-test cDNA 0.10 0.31
MMAB rs2241201 22 0.43/1.0 t-test gDNA 0.83 21.2 20 7.1  1024
t-test cDNA 0.38 34.2 6.5  1023
MVK rs7957619 16 0.10/1.0 t-test gDNA 1.0 10.7 5.7 0.10
t-test cDNA 1.0 16.8 0.21
KCTD10 rs1477117 21 0.15/1.0 t-test gDNA 1.0 14.6 2.9 0.68
t-test cDNA 0.96 12.8 0.47
UBE3B rs7298565b 19 1.0/1.0 t-test gDNA 1.0 5.0 1.4 0.29
UBE3B rs2058807 19 1.0/1.0 t-test gDNA 1.0 13.2 0.07 0.73
ACACB rs3742023 34 0.23/0.75 t-test gDNA 0.93 9.7 3.7 0.051
t-test cDNA 0.89 10.3 0.44
F-test cDNA 0.71 0.47
ACACB rs7135947 14 0.001/0.05 F-test cDNA 0.69 28 1.7 0.40
t-test gDNA 0.009 0.87
SNP, single nucleotide polymorphism; AEI, allelic expression imbalance.
ar2 and D0 values calculated based on observed hepatocyte genotypes for all samples; brs7298565 is used as a representative HDL-C-associated; cpower to detect
AEI size observed for MMAB SNP rs11067231; dSNP and also as a transcribed SNP in UBE3B.
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because the compared values are all based on cDNA. Testing
transcribed SNPs with varying degrees of LD with the
trait-associated SNP should allow evaluation of any possible
bias in the more powerful test. For studies in which phase can
be determined across markers with high accuracy, testing the
phased samples for allelic expression differences could provide
greater power.
AEI may have more power to detect allelic effects on
mRNA level compared with stratifying mRNA level by geno-
type. AEI offers increased sensitivity because each sample
acts as its own internal control for sample-to-sample differ-
ences in cellular environment. In contrast, total mRNA
levels can be influenced by inter-individual variation that
arises from differences in environmental factors, physiological
states, trans-acting factors or overall gene expression between
individuals of different ancestry. We observed stronger evi-
dence for association of rs7298565 allele with transcript level
using AEI (PgDNA ¼ 1.4  10
213, n ¼ 45) than by evaluating
total MMAB mRNA level stratified by genotype (P ¼ 0.0081,
n ¼ 89). The observation of increased MMAB protein with
each copy of the G allele of rs7298565 is consistent with
observations at the mRNA level and provides further support
for a regulatory variant being responsible for the association
with HDL-C level at this locus.
These results provide evidence of AEI in human hepatocytes
and suggest a cis-acting SNP affects expression of MMAB.
MMAB is expressed in many tissues, with high expression in
the liver, which may be most relevant for processes influencing
cholesterol level. Tests for the presence of AEI in other cell
types important in regulating HDL-C level may produce differ-
ent results. Expression quantitative trait locus (eQTL) studies
also detected association of rs7298565 with MMAB expression
in 400 human liver samples (P ¼ 5.5  10215), a result con-
firmed in 950 liver samples (P ¼ 4  10223; 2,19), but not all
genome-wide eQTL analyses of primary or transformed lym-
phocytes reported SNP association with MMAB (9,13,14). In
addition, a recent genome-wide study in lymphoblastoid cell
lines detected association between SNPs in moderate LD with
rs7298565 (r2 ¼ 0.11–0.67; D0 ¼ 1) and allelic expression in
unspecified genes located in a 167 kb region that includes
MMAB, MVK, UBE3B and KCTD10 (18). Further study is
necessary to determine the strength of association between
HDL-C associated SNPs and MMAB expression in other
cell types.
Figure 1. Statistical tests for analysis of AEI depend on LD between transcribed tested SNPs and HDL-C-associated SNPs (cartoon). All tested samples are
heterozygous for the transcribed SNP. cDNA samples are stratified by genotype of the HDL-C-associated SNP (rSNP, x-axis). Percent allele of the transcribed
SNP is displayed on the y-axis. Scenario 1, r2  1, D0 ¼ 1; Scenario 2, r2 1, D0 ¼ 1; Scenario 3, r2 1, D0 , 1; Scenario 4, linkage equilibrium. For ease of
display, the mean of gDNA is assumed to be 50%, whereas in real data mean of gDNA can deviate from 50% due to differences in chemistries of fluorescent
probe binding for each allele.
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Figure 2. Only SNPs in MMAB display significant AEI. AEI was measured using real-time PCR. Significant (P , 0.05) AEI was observed for transcribed SNPs
in MMAB (A–D), but not for transcribed SNPs in other genes (E–J, see Table 1 for P-values). Shown on the x-axis are alleles of the rSNP rs7298565 where
allele A corresponds to rSNP allele A and allele G corresponds to rSNP allele a as defined in the statistical analysis section of the methods. Data is shown as
collected; all P-values were calculated based on a normalized scale (Materials and Methods).
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The role of MMAB in HDL-C biology is unclear. MMAB is
a mitochondrial enzyme that catalyzes conversion of vitamin
B12 into its active form, adenosylcobalamin (4). MMAB is
an essential participant in the catabolism of certain amino
acids, short chain fatty acids and the side chain of cholesterol
to the citric acid cycle intermediate succinyl-CoA (20). An
increase in expression of MMAB might therefore be expected
to lower levels of total cholesterol, including levels of
HDL-C. Given the severity of methylmalonic acidemia, a
disorder resulting from deleterious mutations leading to
impaired MMAB activity (21), and the evidence presented
here of cis-acting variation in MMAB expression, we hypoth-
esize that a variant in high LD with the HDL-C-associated
SNP rs7298565 is likely to be a rSNP that has a modest
effect on synthesis or stability of mRNA.
Our data cannot completely exclude the biological candi-
date MVK, nor the other nearby genes KCTD10, UBE3B and
ACACB, as functional targets of an HDL-C-associated SNP.
Figure 3. Higher hepatocyte MMAB mRNA level is associated with the G allele of rs7298565. Hepatocyte cDNA was analyzed by real-time PCR using gene-
specific primers for MMAB (A), MVK (B), UBE3B (C), KCTD10 (D), ACACB (E), GUSB and B2M. mRNA level was normalized to B2M and GUSB mRNA.
Boxplots extend from the first quartile to the third quartile; the median is indicated as a horizontal line; whiskers are drawn to a distance of 1.5 times the inter-
quartile distance or to the highest or lowest point, whichever is shorter. Mean MMAB mRNA level increased with each G allele of HDL-C-associated SNP
rs7298565.
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Of the transcribed SNPs tested in our study, rs7957619 in
MVK had the lowest MAF and only 16 heterozygote
samples were available. We had 100% power to detect AEI
in MVK based on the amount of AEI observed in MMAB. A
recent study in mice reports that Mmab and Mvk share a con-
served promoter region and are both regulated by binding of
sterol regulatory element binding protein 2, suggesting a
potential novel link between the functions of these genes
(22). In humans, MVK and MMAB are also arranged in a
head-to-head orientation on chromosome 12 and are predicted
to share a 258 bp bidirectional promoter (L. Elnitski, Ph.D,
unpublished data, 2008). Although neither our data nor exist-
ing liver eQTL data (2,21) suggest evidence of cis-acting regu-
lation in MVK, chromosome 12 HDL-C-associated variants
could regulate levels of MVK in untested tissues or through
functional effects unrelated to total mRNA levels.
A primary challenge remains to identify the functional
SNP(s) that affect MMAB transcript levels at this HDL-C
locus. Associated SNPs include a non-synonymous SNP in
MMAB, rs9593. Although both alleles of rs9593, encoding
lysine and methionine, are predicted to have normal physio-
logical activity (20), we cannot exclude that this variant may
also affect HDL-C level.
In summary, these data show that increased expression of
MMAB is associated with SNPs associated with decreased
HDL-C level, strengthening the evidence that MMAB is a
target of an HDL-C-associated SNP and providing evidence
of an effect on protein levels. Further studies are necessary
to identify the functional SNP(s) affecting MMAB, and to




Fresh or cryopreserved lots of human hepatocytes, harvested
from subjects with various causes of death, were purchased
from ADMET Technologies, Inc. (Durham, NC, USA). The
ancestry of collected samples was 76% Caucasian, 12%
African American, 10% Hispanic, 1% Asian and 1% Native
American. Samples were received in four batches. Batches 1
(n ¼ 33) and 4 (n ¼ 9) were received as cryopreserved lots
of cells, batch 2 (n ¼ 12) was received directly after isolation
(fresh) and batch 3 (n ¼ 44) was received as frozen RNA
samples. Initial AEI studies for all SNPs were carried out on
batch 1 samples, and AEI of six SNPs (rs11067231,
rs11067233, rs2241201, rs7957619, rs1477117 and
rs3742023) was further tested on batches 2 and 3. Total
MMAB mRNA levels were measured in all samples. MMAB
protein levels were measured in available samples from
batch 1 (n ¼ 18) and all samples from batches 2 (n ¼ 12)
and 4 (n ¼ 9). The University of North Carolina at Chapel
Hill IRB determined that this study did not require approval.
Isolation of nucleic acids and cDNA preparation
gDNA was isolated using Wizard Genomic DNA purification
kit (Promega, Madison, WI, USA) and total cytosolic RNA
was isolated using Tri reagent (Applied Biosystems, Foster
City, CA, USA). RNA was treated with rDNase I (DNA-free
kit; Applied Biosystems), and DNA and RNA concentrations
were determined using a Nanodrop 1000 (Thermo Scientific,
Wilmington, DE, USA). For real-time reverse transcription
(RT)–PCR, first-strand cDNA was synthesized using 0.8 mg
of total RNA in a 20 ml reverse transcriptase reaction
mixture (Superscript III First strand synthesis kit; Invitrogen,
Carlsbad, CA, USA). cDNA was diluted to contain equivalent
to 4 ng/ml input RNA.
SNP selection and genotyping
Among SNPs strongly associated with HDL-C level in the
chromosome 12 region (3), we selected rs7298565 (r2 ¼ 1
with reported SNP, rs2338104) as a tag SNP to minimize
the number of SNPs to be tested. One to four transcribed
SNPs were selected for each gene in which AEI was to be
tested. To maximize the number of informative heterozygous
samples, transcribed SNPs with minor allele frequencies
.0.1 in HapMap CEU [Utah residents with ancestry from
northern and Western Europe (CEPH sample)] were chosen.
SNPs in strong LD (r2 . 0.8, D0 ¼ 1.0; HapMap CEU
samples) with the HDL-C-associated SNP were given prefer-
ence as they were expected to have the highest power to
detect AEI and the direction of the AEI could be observed.
Genotyping of gDNA samples were performed with TaqMan
allelic discrimination assays (Applied Biosystems) according
to manufacturer’s instructions.
Real-time PCR for AEI and total mRNA levels
Hepatic expression of MMAB, MVK, UBE3B, KCTD10 and
ACACB was confirmed using real-time PCR (M. Fogarty,
Figure 4. Higher hepatocyte MMAB protein level is associated with the G
allele of rs7298565. Hepatocyte protein was analyzed by western blotting
using antibodies directed against MMAB and b-actin. MMAB level was nor-
malized to level of b-actin. (A) Representative gel showing MMAB and
b-actin levels. Lanes 1–2, rs7298565 AA; lanes 3–4, rs7298565 AG; lanes
5–6, rs7298565 GG. (B) Vertical scatter plots for 9 AA, 19 AG and 8 GG
independent observations. Mean MMAB protein level increased with each
G allele of HDL-C-associated SNP rs7298565.
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unpublished data) and published expression array data (23).
All PCR reactions were performed in triplicate in a 10 ml
volume using a 7900 real-time PCR system. Allele-specific
PCR was carried out on hepatocyte gDNA and cDNA using
TaqMan allelic discrimination assays (as above).
To confirm that each assay could detect both alleles in a
usable range, a standard curve was generated. gDNA from
samples homozygous for each of the two alleles, represented
by B and b, corresponding to the VIC and FAM fluorescent
reporters, were mixed in seven different ratios 210:90,
20:80, 40:60, 50:50, 60:40, 80:20 and 90:10. The standard
curve was generated from observed percent allele B versus
input ratio of allele B:b. Percent allele B in each experimental
sample was estimated from the standard curve, and percent
allele b was calculated as 100% 2 percent allele B. Under
idealized conditions the observed percent allele B in heterozy-
gous gDNA would be 50%. Deviation from 50% allele B indi-
cates differences due to labeling and annealing efficiencies of
allele-specific probes. To measure total mRNA levels, gene-
specific primers were used for MMAB, MVK, UBE3B,
KCTD10 and ACACB (Supplementary Material, Table S4).
Serial 10-fold dilutions of cDNA from five pooled hepatocyte
samples were used as a reference for a standard curve.
Western blotting
Protein was isolated according to the manufacturer’s instruc-
tions (Supplemental Methods). Proteins were resolved by
SDS/PAGE and transferred to PVDF membranes (Invitrogen).
Membranes were probed with a mouse polyclonal antibody
raised against full-length human MMAB protein and a rabbit
polyclonal antibody raised against a synthetic peptide
derived from human b-actin (Novus Biologicals, Littleton,
CO, USA), followed by goat anti-mouse or anti-rabbit anti-
bodies conjugated to Alexa Fluor 680 (Invitrogen) or IRdye
800 (Rockland, Gilbertsville, PA, USA). To confirm the speci-
ficity of MMAB detection, a control experiment was per-
formed using an MMAB blocking peptide. Proteins were
detected using an Odyssey imaging system (LI-COR,
Lincoln, NE, USA). MMAB (27 kDa) and b-actin
(43 kDa) bands were quantified by densitometry (LI-COR
software).
Statistical analysis
We describe three tests for AEI that differ both in their potential
for providing unbiased AEI estimates and in their power to
detect AEI, depending on the LD between the transcribed
SNP and the HDL-C-associated potential rSNP. All samples
tested are heterozygous for the transcribed SNP. To correct
for testing multiple hypotheses, we set the significance level
to 0.007 to account for the varying levels of LD between
seven SNPs tested across five genes. Assume the transcribed
SNP has alleles B and b and the rSNP has alleles A and a. In
the absence of both AEI and experimental bias, the %B/%b
ratio should have a mean of 1. To account for experimental
bias, we normalized the observed gDNA or cDNA %B/%b
ratio by dividing it by the mean %B/%b ratio of gDNA from
individuals heterozygous for the transcribed SNP. The normal-
ized %B allele [%Bn ¼ normalized ratio/(1þ normalized
ratio)) was used for all AEI tests. In each test, we compared
the %Bn allele in samples expected to show AEI due to the
rSNP (cDNA from samples heterozygous for the transcribed
SNP) to the %Bn allele in samples not expected to be influenced
by the rSNP (gDNA from samples heterozygous for the tran-
scribed SNP or cDNA from samples homozygous for the tran-
scribed SNP, termed reference samples). We used a two-sided
t-test (gDNA t-test or cDNA t-test) to compare the reference
samples to the cDNA from samples heterozygous for the tran-
scribed SNP, or a one-sided F-test for increased %Bn allele var-
iance in cDNA samples heterozygous for the rSNP relative to
those homozygous for the rSNP (cDNA F-test).
The gDNA t-test can be applied to all transcribed SNPs and
can detect AEI when there is little to no recombination (D0 
1, Scenarios 1 and 2 and some Scenario 3, Fig. 1). For the
reference group, we used the gDNA from samples heterozy-
gous for the transcribed SNP. When D0  1 and AEI is
present, the %Bn allele in the cDNA from samples heterozy-
gous for the rSNP should, on average, deviate in one direction
(higher or lower) from the average %Bn allele in the reference
group. We compared the mean %Bn allele in the reference
group to the group of samples heterozygous for the rSNP
using a two-sided t-test. The number of cDNA samples hetero-
zygous for the rSNP is highest when r2 ¼ 1 (Scenario 1).
The cDNA t-test can be applied to SNPs with one or more
cDNA samples homozygous for the rSNP and may detect AEI
when D0  1, r2 , 1, Scenarios 2 and 3 (Fig. 1). For the refer-
ence group, we used cDNA from samples homozygous for the
rSNP. We compared the mean %Bn allele in the reference
group to the group of samples heterozygous for the rSNP
using a two-sided t-test.
The cDNA F-test can be applied to SNPs with cDNA
samples homozygous for the rSNP and can be used when
recombination has occurred between the transcribed and
rSNP (Scenarios 3 and 4, Fig. 1). For the reference group,
we used cDNA from all samples homozygous for the rSNP.
When recombination is present, a sample can contain one of
four haplotype pairs. Two pairs are homozygous for the
rSNP (AB/Ab and aB/ab) and two heterozygous (AB/ab and
aB/Ab). These latter two pairs cannot be distinguished based
on the observed genotype data. If AEI is present within
cDNA from samples heterozygous for the rSNP, the AB/ab
haplotype pair will deviate from the reference group in one
direction and the aB/Ab haplotype pair in the opposite direc-
tion. We used a one-sided F-test of variance to test for
higher variance of the %Bn allele in the cDNA of samples het-
erozygous for the rSNP than in those homozygous for the
rSNP.
We performed all plausible tests on each SNP: gDNA t-test
(Scenarios 1–4, Figure 1), cDNA test (Scenarios 2–4) and
cDNA F-test (Scenarios 3 and 4).
To determine the power to detect AEI of a specified amount
in samples heterozygous for each transcribed SNP, we simu-
lated data based on (i) the number of cDNA samples with
each rSNP genotype, (ii) the number of genotyped gDNA
samples heterozygous for the transcribed SNP, (iii) the standard
deviation (SD) of the %Bn allele observed for gDNA and cDNA
from specified sets of samples and (iv) the observed LD
between the transcribed SNP and the rSNP. We used the tests
described above to analyze the simulated data. For each
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transcribed SNP, we also determined the AEI necessary to
obtain 80% power (Supplemental Methods).
For analysis of total mRNA levels, raw expression data
were adjusted based on the average expression of two house-
keeping genes, B2M and GUSB, and log10 transformed to
approximate normality. We tested for association between
mRNA level and the number of rs7298565 G alleles using
linear regression. Age, sex, self-reported ancestry and
sample batch (described above) were considered as covariates.
For analysis, levels of MMAB protein were normalized for
b-actin levels and log transformed to approximate normality.
We tested for association between MMAB protein level and
the number of rs7298565 G alleles using linear regression.
Sample batch was not included as a covariate as no significant
association was observed between protein levels and sample
batch.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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